Arcellx, Inc. (ACLX) Dividend History

Company News

• New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs

  The article discusses the growing cancer treatment market, with a focus on companies like Oncolytics Biotech, Akoya Biosciences, Quanterix, TScan Therapeutics, and Arcellx. It highlights new data and collaborations that signal a turning point for precision-driven cancer biotechs.

  Benzinga

  Featured Companies: AKYA ONCY QTRX TCRX
• Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight

  The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.

  GlobeNewswire Inc.

  Featured Companies: ABBV ADCT BMY JNJ KROS MRK REGN SLS
• CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

  The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.

  GlobeNewswire Inc.

  Featured Companies: ALLO DTIL IPSC KYTX RNAC SANA
• Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention

  Gilead Sciences reported strong Q4 2024 results, with revenue and earnings beating consensus. The company raised its 2025 outlook and is preparing for the potential launch of lenacapavir for HIV prevention in 2025, which could strengthen its HIV leadership.

  Benzinga
• Expert Ratings For Arcellx

  Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Arcellx (NASDAQ:ACLX) in the last three months. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 8 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 4 1 0 0 0 2M Ago 1 0 0 0 0 3M Ago 3 1 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $81.09, a high estimate of $87.00, and a low estimate of $70.00. Observing a 10.7% increase, the current average has risen from the previous average price target of $73.25. Investigating Analyst Ratings: An Elaborate Study In examining recent analyst actions, we gain insights into how financial experts perceive Arcellx. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Biren Amin Piper Sandler Announces Overweight $70.00 - Benjamin Burnett Stifel Raises Buy $83.00 $82.00 Cory Kasimov Evercore ISI Group Announces Outperform $85.00 - Emily Bodnar HC Wainwright & Co. Lowers Buy $80.00 $82.00 Gil Blum Needham Maintains Buy $81.00 - Gil Blum Needham Maintains Buy $81.00 - Gil Blum Needham Maintains Buy $81.00 - Gil Blum Needham Raises Buy $81.00 $72.00 Benjamin Burnett Stifel Maintains Buy $82.00 - Judah Frommer Morgan Stanley Announces Overweight $81.00 - Asthika Goonewardene Truist Securities Raises Buy $87.00 $57.00 Key Insights: Action Taken: In response ...Full story available on Benzinga.com

  Benzinga